Genome-wide biomarker analysis across the full spectrum of HER2-expressing breast cancers to reveal a clonal chromosome 17 imbalance defining unfavourable HER2-low disease
A specific chromosomal pattern identifies high-risk breast cancers that might benefit most from targeted HER2 therapies.
Using genome-wide single-cell DNA sequencing in a cohort of HER2-expressing breast tumors, a specific clonal chromosome 17 imbalance was identified as a biomarker distinguishing a high-risk HER2-low subgroup. These findings have implications for refining patient selection for trastuzumab deruxtecan (T-DXd) and other HER2-directed therapies in the rapidly expanding HER2-low population.
What the study was
- Study design
- Genome-wide single-cell DNA sequencing biomarker analysis; retrospective cohort
- Population
- Breast cancer patients across the full HER2 expression spectrum (HER2-zero, HER2-low, HER2-positive)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Biomarker Research
Why it surfaced
HER2-low is a rapidly growing therapeutic category (T-DXd); genomic biomarker stratification within HER2-low could refine patient selection in near-term clinical practice.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.